Posters of our products:

  1. Alonso-Camino V, Vanderwielen J, Ben S, et al. Expansion of Different Types of Therapeutic Cells Using Xenogeneic Free and Gamma Irradiated Human Platelet Lysate. Poster presented at: ISCT Annual Meeting. San Francisco, CA, USA. 2022 May.

  2. Alonso-Camino V, Mirsch W. Development of a gamma irradiated human platelet lysate for high efficiency cGMP expansion of therapeutic stem cells. Poster presented at: ISCT Annual Meeting. New Orleans Virtual. 2021 May.

  3. Alonso-Camino V, Mirsch W. Development of Standard Protocol for the cGMP Production of Human Mesenchymal Stem/Stromal Cells from Different Source Tissues. Poster presented at: ISCT Annual Meeting. Paris Virtual. 2020 May.

  4. Alonso-Camino V, Mirsch W. Development of Technology for the Large Scale Production of a Novel Dendritic Cell Vaccine for the Treatment of Glioblastoma. Poster presented at: 2019 International Cancer Immunotherapy Conference. Paris, France. 2019 September.

  5. Alonso-Camino V, Mirsch W. Rapid expansion of Mesenchymal Stem/Stromal Cells using optimized media supplemented with human platelet lysate PLTMax® or PLTGold®, suitable for cGMP expansion at large scale. Poster presented at: ISCT Annual Meeting. Melbourne, Australia. 2019 May.

  6. Gandhi JK, Knudsen T, Hill M, et al. Comparison of Fetal Bovine Serum and PLTMax® for Long Term Maintenance of Human Induced Pluripotent Stem Cell Derived Retinal Pigment Epithelial Cells. Poster presented at: ISSCR Annual Meeting. Melbourne, Australia. 2018 June.

  7. Alonso-Camino V, Mirsch W. In vitro expansion of human primary endothelial cells for clinical use using EndoGo™ XF Medium supplemented with PLTGold® human platelet lysate. Poster presented at: ISCT Annual Meeting. Montreal, Canada. 2018 May.

  8. Bulur P, Wiltshire T, Dudakovic A, et al. Impact of media supplementation on the secretion of IFN-γ induced indoleamine 2-3 deoxygenase and resultant immune suppression by mesenchymal stromal cells. Poster presented at: ISCT Annual Meeting. Montreal, Canada. 2018 May.

  9. Alonso-Camino V, Thornberry Kent L. Expansion of MSCs for Translational Medicine using MSC NutriStem® Basal Medium and PLTMax® Human Platelet Lysate. Poster presented at: ISSCR Annual Meeting. Boston, MA, USA. 2017 June.

  10. Alonso-Camino V, Clarke B, Nielsen J, et al. In vitro expansion of mesenchymal stem cells using media supplemented with unfractionated heparin-free platelet lysate. Poster presented at: ISCT Annual Meeting. London, UK. 2017 May.


Publications referencing our products:

  1. Blitzer GC, Rogus-Pulia NM, Mattison RJ, et al. Marrow-Derived Autologous Stromal Cells for the Restoration of Salivary Hypofunction (MARSH): Study protocol for a phase 1 dose-escalation trial of patients with xerostomia after radiation therapy for head and neck cancer: MARSH: Marrow-Derived Autologous Stromal Cells for the Restoration of Salivary Hypofunction. Cytotherapy. 2022 May; 24(5):534-543. doi: 10.1016/j.jcyt.2021.11.003.

  2. Lei T, Liu Y, Deng S, et al. Hydrogel supplemented with human platelet lysate enhances multi-lineage differentiation of mesenchymal stem cells. J Nanobiotechnology. 2022 Apr 2;20(1):176. doi: 10.1186/s12951-022-01387-9.

  3. Atanasova E, Milosevic D, Bornschlegl S, et al. Normal ex vivo mesenchymal stem cell function combined with abnormal immune profiles sets the stage for informative cell therapy trials in idiopathic pulmonary fibrosis patients. Stem Cell Res Ther. 2022 Jan 31;13(1):45. doi: 10.1186/s13287-021-02692-0.

  4. Lanzoni G, Linetsky E, Correa D, et al. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial. Stem Cells Transl Med. 2021 May;10(5):660-673. doi: 10.1002/sctm.20-0472.

  5. Struijk C, Van Genechten W, Verdonk P, et al. Human meniscus allograft augmentation by allogeneic mesenchymal stromal/stem cell injections. J Orthop Res. 2021 May 10. doi: 10.1002/jor.25074.

  6. Parney IF, Gustafson MP, Solseth M, et al. Novel strategy for manufacturing autologous dendritic cell/allogeneic tumor lysate vaccines for glioblastoma. Neurooncol Adv. 2020 Jan-Dec; 2(1): vdaa105.

  7. Gluscevic M, Paradise CR, Dudakovic A, et al. Functional expression of ZNF467 and PCBP2 supports adipogenic lineage commitment in adipose-derived mesenchymal stem cells. Gene. 2020 Feb 4;737:144437.

  8. Kubrova E, Qu W, Galvan ML, et al. Hypothermia and nutrient deprivation alter viability of human adipose-derived mesenchymal stem cells. Gene. 2020 Jan 5;722:144058.

  9. Zhang Y, Sharma A, Joo DJ, et al. Autologous Adipose Tissue–Derived Mesenchymal Stem Cells Introduced by Biliary Stents or Local Immersion in Porcine Bile Duct Anastomoses. Liver Transpl. 2020 Jan;26(1):100-112.

  10. Abumoawad A, Saad A, Ferguson CM, et al. In a Phase 1a escalating clinical trial, autologous mesenchymal stem cell infusion for renovascular disease increases blood flow and the glomerular filtration rate while reducing inflammatory biomarkers and blood pressure. Kidney Int. 2019 Dec 13. pii: S0085-2538(19)31218-9.

  11. Jordan TL, Maar K, Redhage KR, et al. Light chain amyloidosis induced inflammatory changes in cardiomyocytes and adipose-derived mesenchymal stromal cells. Leukemia. 2019 Dec 3.

  12. Bydon M, Dietz AB, Goncalves S, et al. CELLTOP Clinical Trial: First Report From a Phase 1 Trial of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells in the Treatment of Paralysis Due to Traumatic Spinal Cord Injury. Mayo Clin Proc. 2019 Nov 27. pii: S0025-6196(19)30871-7.

  13. Huang CT, Chu HS, Hung KC, et al. The effect of human platelet lysate on corneal nerve regeneration. Br J Ophthalmol. 2019 Nov 20. pii: bjophthalmol-2019-314408.

  14. Nie H, Kubrova E, Wu T, et al. Effect of Lidocaine on Viability and Gene Expression of Human Adipose-derived Mesenchymal Stem Cells: An in vitro Study. PM R. 2019 Nov;11(11):1218-1227.

  15. Lightner AL, Dozois EJ, Dietz AB, et al. Matrix-Delivered Autologous Mesenchymal Stem Cell Therapy for Refractory Rectovaginal Crohn's Fistulas. Inflamm Bowel Dis. 2019 Oct 12. pii: izz215.

  16. Kakudo N, Morimoto N, Ma Y, et al. Differences between the Proliferative Effects of Human Platelet Lysate and Fetal Bovine Serum on Human Adipose-Derived Stem Cells. Cells. 2019 Oct 8;8(10). pii: E1218.

  17. Conley SM, Shook JE, Zhu XY, et al. Metabolic Syndrome Induces Release of Smaller Extracellular Vesicles from Porcine Mesenchymal Stem Cells. Cell Transplant. 2019 Sep-Oct;28(9-10):1271-1278.

  18. Hickson LJ, Langhi Prata LGP, Bobart SA, et al. Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine. 2019 Sep;47:446-456.

  19. Suvakov S, Cubro H, White WM, et al. Targeting senescence improves angiogenic potential of adipose-derived mesenchymal stem cells in patients with preeclampsia. Biol Sex Differ. 2019 Sep 14;10(1):49.

  20. Rbia N, Bulstra LF, Lewallen EA, et al. Seeding decellularized nerve allografts with adipose-derived mesenchymal stromal cells: An in vitro analysis of the gene expression and growth factors produced.  J Plast Reconstr Aesthet Surg. 2019 Aug;72(8):1316-1325.

  21. Mathot F, Shin AY, Van Wijnen AJ. Targeted stimulation of MSCs in peripheral nerve repair. Gene. 2019 Aug 20;710:17-23.

  22. Gómez-de Frutos MC, Laso-García F, Diekhorst L, et al. Intravenous delivery of adipose tissue-derived mesenchymal stem cells improves brain repair in hyperglycemic stroke rats. Stem Cell Res Ther. 2019 Jul 17;10(1):212.

  23. Singer W, Dietz AB, Zeller AD, et al. Intrathecal administration of autologous mesenchymal stem cells in multiple system atrophy. Neurology. 2019 Jul 2;93(1):e77-e87.

  24. Boland LK, Burand AJ, Boyt DT, et al. Nature vs. Nurture: Defining the Effects of Mesenchymal Stromal Cell Isolation and Culture Conditions on Resiliency to Palmitate Challenge. Front Immunol. 2019 May 10;10:1080.

  25. Dozois EJ, Lightner AL, Mathis KL, et al. Early Results of a Phase I Trial Using an Adipose-Derived Mesenchymal Stem Cell-Coated Fistula Plug for the Treatment of Transsphincteric Cryptoglandular Fistulas. Dis Colon Rectum. 2019 May;62(5):615-622.

  26. Pawar AS, Eirin A, Krier JD, et al. Alterations in genetic and protein content of swine adipose tissue-derived mesenchymal stem cells in the Metabolic Syndrome. Stem Cell Res. 2019 May;37:101423. 

  27. Eirin A, Zhu XY, Woollard JR, et al. Metabolic Syndrome Interferes with Packaging of Proteins within Porcine Mesenchymal Stem Cell-Derived Extracellular Vesicles. Stem Cells Transl Med. 2019 May;8(5):430-440.

  28. Reis M, Mavin E, Nicholson L, et al. Mesenchymal Stromal Cell-Derived Extracellular Vesicles Attenuate Dendritic Cell Maturation and Function. Front Immunol. 2018 Nov 9;9:2538.

  29. Rbia N, Bulstra LF, Thaler R, et al. In Vivo Survival of Mesenchymal Stromal Cell-Enhanced Decellularized Nerve Grafts for Segmental Peripheral Nerve Reconstruction. J Hand Surg Am. 2018 Oct 6. pii: S0363-5023(17)32175-5.

  30. Meng Y, Eirin A, Zhu XY, et al. Micro-RNAS Regulate Metabolic Syndrome-induced Senescence in Porcine Adipose Tissue-derived Mesenchymal Stem Cells through the P16/MAPK Pathway. Cell Transplant. 2018 Oct;27(10):1495-1503.

  31. Aghajani Nargesi A, Zhu XY, Hickson LJ, et al. Metabolic Syndrome Modulates Protein Import into the Mitochondria of Porcine Mesenchymal Stem Cells. Stem Cell Rev. 2018 Oct 18.

  32. Meng Y, Eirin A, Zhu XY, et al. The metabolic syndrome modifies the mRNA expression profile of extracellular vesicles derived from porcine mesenchymal stem cells. Diabetol Metab Syndr. 2018 Jul 21;10:58.

  33. Eirin A, Zhu XY, Jonnada S, et al. Mesenchymal Stem Cell-Derived Extracellular Vesicles Improve the Renal Microvasculature in Metabolic Renovascular Disease in Swine. Cell Transplant. 2018 Jul;27(7):1080-1095.

  34. Samsonraj R, Paradise CR, Dudakovic A, et al. Validation of osteogenic properties of Cytochalasin D by high-resolution RNA-sequencing in mesenchymal stem cells derived from bone marrow and adipose tissues. Stem Cells Dev. 2018 Jun 8.

  35. Wu T, Nie H, Dietz AB, et al. Cytotoxic Effects of Nonionic Iodinated Contrast Agent on Human Adipose-Derived Mesenchymal Stem Cells. PM R. 2018 Jun 1. pii: S1934-1482(18)30294-6.

  36. Zou X, Jiang K, Puranik AS, et al. Targeting Murine Mesenchymal Stem Cells to Kidney Injury Molecule-1 Improves Their Therapeutic Efficacy in Chronic Ischemic Kidney Injury. Stem Cells Transl Med. 2018 May;7(5):394-403.

  37. Su Y, Denbeigh JM, Camilleri ET, et al. Extracellular matrix protein production in human adipose-derived mesenchymal stem cells on three-dimensional polycaprolactone (PCL) scaffolds responds to GDF5 or FGF2. Gene Rep. 2018 Mar; 10:149-156.

  38. Chen LW, Huang CJ, Tu WH, et al. The corneal epitheliotrophic abilities of lyophilized powder form human platelet lysates. PLoS ONE. 2018 Mar 16;13(3): e0194345.

  39. Marmorstein AD, Johnson AA, Bachman LA, et al. Mutant Best1 Expression and Impaired Phagocytosis in an iPSC Model of Autosomal Recessive Bestrophinopathy. Sci Rep. 2018 Mar 14;8(1):4487.

  40. Reis M, McDonald D, Nicholson L, et al. Global phenotypic characterisation of human platelet lysate expanded MSCs by high-throughput flow cytometry. Sci Rep. 2018; 8: 3907.

  41. Samsonraj R, Dudakovic A, Manzar B, et al. Osteogenic Stimulation of Human Adipose-Derived Mesenchymal Stem Cells Using a Fungal Metabolite That Suppresses the Polycomb Group Protein EZH2. Stem Cells Transl Med. 2017 Dec 27.

  42. Kuroki LM, Jin X, Dmitriev IP, et al. Adenovirus platform enhances transduction efficiency of human mesenchymal stem cells: An opportunity for cellular carriers of targeted TRAIL-based TR3 biologics in ovarian cancer. PLoS One. 2017 Dec 21;12(12):e0190125.

  43. Lin Y, Marin-Argany M, Dick CJ, et al. Mesenchymal stromal cells protect human cardiomyocytes from amyloid fibril damage. Cytotherapy. 2017 Oct. pii: S1465-3249(17)30695-3.

  44. Saad A, Dietz AB, Herrmann SMS, et al. Autologous Mesenchymal Stem Cells Increase Cortical Perfusion in Renovascular Disease. J Am Soc Nephrol. 2017 Sep;28(9):2777-2785.

  45. Galeano-Garces C, Camilleri ET, Riester SM, et al. Molecular Validation of Chondrogenic Differentiation and Hypoxia Responsiveness of Platelet-Lysate Expanded Adipose Tissue-Derived Human Mesenchymal Stromal Cells. Cartilage. 2017 Jul;8(3):283-299.

  46. Dudakovic A, Gluscevic M, Paradise CR, et al. Profiling of human epigenetic regulators using a semi-automated real-time qPCR platform validated by next generation sequencing. Gene. 2017 Apr 20;609:28-37.

  47. Guess AJ, Daneault B, Wang R, et al. Safety Profile of Good Manufacturing Practice Manufactured Interferon γ-Primed Mesenchymal Stem/Stromal Cells for Clinical Trials. Stem Cells Transl Med. 2017 Oct;6(10):1868-1879.

  48. Quintas-Cardama A, Hu C, Qutub A, et al. p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status. Leukemia. 2017 Jun;31(6):1296-1305.

  49. ​​Dietz AB, Dozois EJ, Fletcher JG, et al. Autologous Mesenchymal Stem Cells, Applied in a Bioabsorbable Matrix, for Treatment of Perianal Fistulas in Patients With Crohn's Disease'. Gastroenterology. 2017 Apr 8. pii: S0016-5085(17)35411-2.

  50. Riester SM, Denbeigh JM, Lin Y, et al. Safety Studies for Use of Adipose Tissue-Derived Mesenchymal Stromal/Stem Cells in a Rabbit Model for Osteoarthritis to Support a Phase I Clinical Trial. Stem Cells Transl Med. 2017 Mar;6(3):910-922.

  51. Eirin A, Zhu XY, Puranik AS, et al. Integrated transcriptomic and proteomic analysis of the molecular cargo of extracellular vesicles derived from porcine adipose tissue-derived mesenchymal stem cells. PLoS One. 2017 Mar 23;12(3):e0174303.

  52. Huang CJ, Sun YC, Christopher K, et al. Comparison of corneal epitheliotrophic capacities among human platelet lysates and other blood derivatives. PLoS One. 2017 Feb 2;12(2):e0171008.

  53. Maria S, Swanson MH, Enderby LT, et al. Melatonin-micronutrients Osteopenia Treatment Study (MOTS): a translational study assessing melatonin, strontium (citrate), vitamin D3 and vitamin K2 (MK7) on bone density, bone marker turnover and health related quality of life in postmenopausal osteopenic women following a one-year double-blind RCT and on osteoblast-osteoclast co-cultures. Aging (Albany NY). 2017 Jan 26;9(1):256-285.

  54. Staff NP, Madigan NN, Morris J, et al. Safety of intrathecal autologous adipose-derived mesenchymal stromal cells in patients with ALS. Neurology. 2016 Nov 22;87(21):2230-2234.

  55. Hsueh YJ, Huang SF, Lai JY, et al. Preservation of epithelial progenitor cells from collagenase-digested oral mucosa during ex vivo cultivation. Sci Rep. 2016 Nov 8;6:36266.

  56. Eirin A, Zhu XY, Puranik AS, et al. Comparative proteomic analysis of extracellular vesicles isolated from porcine adipose tissue-derived mesenchymal stem/stromal cells. Sci Rep. 2016 Oct 27;6:36120.

  57. Aho JM, Dietz AB, Radel DJ, et al. Closure of a Recurrent Bronchopleural Fistula Using a Matrix Seeded With Patient-Derived Mesenchymal Stem Cells. Stem Cells Transl Med. 2016 Oct;5(10):1375-1379.

  58. Saad A, Zhu XY, Herrmann S, et al. Adipose-derived mesenchymal stem cells from patients with atherosclerotic renovascular disease have increased DNA damage and reduced angiogenesis that can be modified by hypoxia. Stem Cell Res Ther. 2016 Sep 9;7(1):128.

  59. Onishi K, Jones DL, Riester SM, et al. Human Adipose-Derived Mesenchymal Stromal/Stem Cells Remain Viable and Metabolically Active Following Needle Passage. PM R. 2016 Sep;8(9):844-54.

  60. Camilleri ET, Gustafson MP, Dudakovic A, et al. Identification and validation of multiple cell surface markers of clinical-grade adipose-derived mesenchymal stromal cells as novel release criteria for good manufacturing practice-compliant production. Stem Cell Res Ther. 2016 Aug 11;7(1):107.

  61. Zhu XY, Ma S, Eirin A, et al. Functional Plasticity of Adipose-Derived Stromal Cells During Development of Obesity. Stem Cells Transl Med. 2016 Jul;5(7):893-900.

  62. Lewallen EA, Jones DL, Dudakovic A, et al. Osteogenic potential of human adipose-tissue-derived mesenchymal stromal cells cultured on 3D-printed porous structured titanium. Gene. 2016 May 1;581(2):95-106.

  63. Yang B, Brahmbhatt A, Nieves Torres E, et al. Tracking and Therapeutic Value of Human Adipose Tissue-derived Mesenchymal Stem Cell Transplantation in Reducing Venous Neointimal Hyperplasia Associated with Arteriovenous Fistula. Radiology. 2016 May;279(2):513-22.

  64. Juhl M, Tratwal J, Follin B, et al. Comparison of clinical grade human platelet lysates for cultivation of mesenchymal stromal cells from bone marrow and adipose tissue. Scand J Clin Lab Invest. 2016;76(2):93-104.

  65. Dudakovic A, Camilleri ET, Xu F, et al. Epigenetic Control of Skeletal Development by the Histone Methyltransferase Ezh2. J Biol Chem. 2015 Nov 13;290(46):27604-17.

  66. Wagner ER, Bravo D, Dadsetan M, et al. Ligament Tissue Engineering Using a Novel Porous Polycaprolactone Fumarate Scaffold and Adipose Tissue-Derived Mesenchymal Stem Cells Grown in Platelet Lysate. Tissue Eng Part A. 2015 Nov;21(21-22):2703-13.

  67. Zhu XY, Ebrahimi B, Eirin A, et al. Renal Vein Levels of MicroRNA-26a Are Lower in the Poststenotic Kidney. J Am Soc Nephrol. 2015 Jun;26(6):1378-88.

  68. Chen BK, Staff NP, Knight AM, et al. A safety study on intrathecal delivery of autologous mesenchymal stromal cells in rabbits directly supporting Phase I human trials. Transfusion. 2015 May;55(5):1013-20.

  69. Dudakovic A, Camilleri ET, Lewallen EA, et al. Histone deacetylase inhibition destabilizes the multi-potent state of uncommitted adipose-derived mesenchymal stromal cells. J Cell Physiol. 2015 Jan;230(1):52-62.

  70. Eirin A, Riester SM, Zhu XY, et al. MicroRNA and mRNA cargo of extracellular vesicles from porcine adipose tissue-derived mesenchymal stem cells. Gene. 2014 Nov 1;551(1):55-64.

  71. Dudakovic A, Camilleri E, Riester SM, et al. High-resolution molecular validation of self-renewal and spontaneous differentiation in clinical-grade adipose-tissue derived human mesenchymal stem cells. J Cell Biochem. 2014 Oct;115(10):1816-28.

  72. Eirin A, Zhang X, Zhu XY, et al. Renal vein cytokine release as an index of renal parenchymal inflammation in chronic experimental renal artery stenosis. Nephrol Dial Transplant. 2014 Feb;29(2):274-82.

  73. Bartunek J, Behfar A, Dolatabadi D, et al. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol. 2013 Jun 11;61(23):2329-38.

  74. Mader EK, Butler G, Dowdy SC, et al. Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer. J Transl Med. 2013 Jan 24;11:20.

  75. Mertens JC, Fingas CD, Christensen JD, et al. Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma. Cancer Res. 2013 Jan 15;73(2):897-907.

  76. Bao J, Fisher JE, Lillegard JB, et al. Serum-free medium and mesenchymal stromal cells enhance functionality and stabilize integrity of rat hepatocyte spheroids. Cell Transplant. 2013;22(2):299-308.

  77. Crespo-Diaz R, Behfar A, Butler GW, et al. Platelet lysate consisting of a natural repair proteome supports human mesenchymal stem cell proliferation and chromosomal stability. Cell Transplant. 2011;20(6):797-811.

  78. Sunil N, Punreddy S, Niss K, et al. Expansion of Human Mesenchymal Stem Cells Using Microcarriers and Human Platelet Lysate. BioProcess International. 2014 Sep; 12(8):74-78.


Key MSC Review Papers and Classics:

  1. Karnieli O, Friedner OM, Allickson JG, et al. A consensus introduction to serum replacements and serum-free media for cellular therapies. Cytotherapy. 2017 Feb;19(2):155-169.

  2. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-7.

  3. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005 Feb 15;105(4):1815-22.

  4. Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004 May 1;363(9419):1439-41.

  5. Deans RJ, Moseley AB. Mesenchymal stem cells: Biology and potential clinical uses. Exp Hematol. 2000 Aug;28(8):875-84.

  6. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999 Apr 2;284(5411):143-7.

  7. Horwitz EM, Prockop DJ, Fitzpatrick LA, et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med. 1999 Mar;5(3):309-13.